Innate Pharma (IPHA) Cash from Operations (2020 - 2024)
Historic Cash from Operations for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to -$7.4 million.
- Innate Pharma's Cash from Operations rose 7896.46% to -$7.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$128.8 million, marking a year-over-year increase of 2967.33%. This contributed to the annual value of -$7.5 million for FY2024, which is 7880.78% up from last year.
- Innate Pharma's Cash from Operations amounted to -$7.4 million in Q4 2024, which was up 7896.46% from -$35.0 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Cash from Operations registered a high of -$7.4 million during Q4 2024, and its lowest value of -$66.9 million during Q4 2021.
- Over the past 5 years, Innate Pharma's median Cash from Operations value was -$35.0 million (recorded in 2023), while the average stood at -$38.1 million.
- Per our database at Business Quant, Innate Pharma's Cash from Operations plummeted by 7925.51% in 2023 and then soared by 7896.46% in 2024.
- Over the past 5 years, Innate Pharma's Cash from Operations (Quarter) stood at -$61.7 million in 2020, then dropped by 8.35% to -$66.9 million in 2021, then surged by 70.78% to -$19.5 million in 2022, then tumbled by 79.26% to -$35.0 million in 2023, then skyrocketed by 78.96% to -$7.4 million in 2024.
- Its last three reported values are -$7.4 million in Q4 2024, -$35.0 million for Q4 2023, and -$19.5 million during Q4 2022.